Dermata Therapeutics, Inc.
No SEC Form 4 filings for $DRMA in the last 30 days.
See all $DRMA insider activity →Dermata Therapeutics (NASDAQ:DRMA) said its first direct-to-consumer skincare product, Tome Foundational Treatment, is planned to launch Aug. 25, 2026, with waitlist users receiving early preorder access. The set includes four once-weekly treatments using Bioneedle technology, sold exclusively online for $178 (about $45 per treatment).
Dermata Therapeutics Inc. (DRMA) is projected to report a loss of $1.54 per share. This earnings preview provides a brief financial outlook for the company, indicating expectations for its upcoming earnings announcement. The information is sourced from Refinitiv via Reuters.
Dermata Therapeutics Inc. (DRMA) stock has risen by 22.49% following positive FDA designations and trial results, along with plans for a new brand identity and a once-weekly acne kit by mid-2026. The company is also undergoing a private placement to raise capital. While recent financial performance shows a net loss and operating cash flow deficit, Dermata's strategic moves aim to redefine its market position and attract investors.
Over the past 7 days, alphai's AI scored 1 news story mentioning DRMA (Dermata Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
The scheduled launch date and product commercialization details create a near-term catalyst for DRMA’s commercialization narrative and potential investor sentiment.
Dermata Therapeutics Inc. is expected to report a significant loss of $1.54 per share, with a bearish market sentiment indicated by a negative sentiment score of -0.470. This suggests potential downward pressure on the stock in the near term.
Dermata Therapeutics (DRMA) has experienced a 22.49% increase following positive FDA updates and strategic initiatives. The company's plans for a new acne treatment and capital raise suggest potential growth, but financials show net losses and cash flow deficits, indicating underlying risks.
Dermata Therapeutics has secured approximately $3.7 million through financing agreements, supporting growth initiatives including a new OTC acne kit. The company's positive funding news may bolster investor confidence in the near term.
Dermata Therapeutics Inc. experienced an 18.8% after-hours stock increase following a $4.1 million private placement. The company plans to utilize proceeds for research and potential acquisitions, which could positively influence future growth.
alphai scores every news story that mentions DRMA with an AI model for sentiment and relevance, and aggregates insider trades from Dermata Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dermata Therapeutics (NASDAQ:DRMA) said its first direct-to-consumer skincare product, Tome Foundational Treatment, is planned to launch Aug. 25, 2026, with waitlist users receiving early preorder access. The set includes four once-weekly treatments using Bioneedle technology, sold exclusively online for $178 (about $45 per treatment).
2 min readDermata Therapeutics Inc. (DRMA) is projected to report a loss of $1.54 per share. This earnings preview provides a brief financial outlook for the company, indicating expectations for its upcoming earnings announcement. The information is sourced from Refinitiv via Reuters.
2 min readDermata Therapeutics Inc. (DRMA) stock has risen by 22.49% following positive FDA designations and trial results, along with plans for a new brand identity and a once-weekly acne kit by mid-2026. The company is also undergoing a private placement to raise capital. While recent financial performance shows a net loss and operating cash flow deficit, Dermata's strategic moves aim to redefine its market position and attract investors.
4 min readDermata Therapeutics (DRMA) secured approximately $3.7 million in net proceeds through multiple financing agreements related to a private placement. These agreements include a Securities Purchase Agreement with investors for common stock and warrants, a Registration Rights Agreement, and amendments to outstanding warrants. The funds are designated for general corporate purposes, including the launch of a new OTC acne kit and other strategic initiatives.
2 min readDermata Therapeutics Inc. (NASDAQ:DRMA) stock surged 18.8% in after-hours trading after announcing the closure of a $4.1 million private placement. The company issued common stock and warrants, with insiders participating, and plans to use the proceeds for general corporate purposes including consumer research for its new OTC acne kit and potential acquisitions.
2 min readDermata Therapeutics announced the closing of a private placement, raising $4.1 million upfront by issuing shares and warrants, with potential for another $8.3 million if all warrants are exercised. Insiders participated in the offering, and proceeds will fund product launch activities for the company's new OTC acne kit, expected in mid-2026, and general corporate purposes. This financing is part of Dermata's strategic pivot to OTC dermatology, aimed at increasing liquidity and supporting its new acne treatment development.
2 min readDermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September ...
3 min readDermata Therapeutics ( NASDAQ:DRMA ) , a clinical-stage biotech specializing in innovative dermatology therapies, released its earnings on August 13, 2025. The company's primary news item was a narrower net loss than expected, with a GAAP loss per share of $1.66 compared to analyst estimates of ...
2 min read
